AC
ALXN

Apex Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Apex Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$22.9M Buy
120,200
+25,200
+27% +$4.4M 2.45% 17
2015
Q3 		$14.9M Sell
95,000
-24,850
-21% -$4.53M 1.41% 30
2015
Q2 		$21.7M Buy
119,850
+54,850
+84% +$9.47M 1.88% 22
2015
Q1 		$11.3M Buy
+65,000
New +$11.8M 0.81% 48

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Apex Capital's ALXN Position: Q4 2015 in Review

Apex Capital increased its Alexion Pharmaceuticals (ALXN) stake by 27% in Q4 2015, buying an estimated $4.4M and bringing the position to 120,200 shares worth $22.9M. The position accounts for 2.45% of the portfolio, ranked #17.

Apex Capital first reported a position in ALXN in Q1 2015 and has held it in 4 quarters since. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

  • Apex Capital held 120,200 shares of Alexion Pharmaceuticals worth $22.9M as of Q4 2015.
  • Apex Capital bought 25,200 Alexion Pharmaceuticals shares in Q4 2015, an estimated $4.4M.
  • Alexion Pharmaceuticals made up 2.45% of Apex Capital's portfolio in Q4 2015, its #17 holding.
  • Apex Capital first reported a position in Alexion Pharmaceuticals in Q1 2015 and has held it in 4 quarters since.
  • 549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Apex Capital's 13F filing for Q4 2015, filed 16 Feb 2016.